Trial Outcomes & Findings for A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (NCT NCT03334539)

NCT ID: NCT03334539

Last Updated: 2024-03-07

Results Overview

It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

150 participants

Primary outcome timeframe

Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

Results posted on

2024-03-07

Participant Flow

Participants who met all the eligibility criteria were enrolled at 2 sites in the United States.

All participants went through a placebo run-in period for 14 days prior to randomization. During the period, exposures to the controlled adverse environment® (CAE) were conducted to ascertain eligibility to enter the study. Those who qualified were randomized.

Participant milestones

Participant milestones
Measure
0.10% HL036 Ophthalmic Solution
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Overall Study
STARTED
50
50
50
Overall Study
COMPLETED
46
43
49
Overall Study
NOT COMPLETED
4
7
1

Reasons for withdrawal

Reasons for withdrawal
Measure
0.10% HL036 Ophthalmic Solution
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Overall Study
Adverse Event
3
5
0
Overall Study
Withdrawal by Subject
0
1
1
Overall Study
Administrative Reasons
1
0
0
Overall Study
Hypertension Not Controlled
0
1
0

Baseline Characteristics

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Total
n=150 Participants
Total of all reporting groups
Age, Continuous
60.9 years
STANDARD_DEVIATION 13.09 • n=99 Participants
63.5 years
STANDARD_DEVIATION 9.92 • n=107 Participants
66.1 years
STANDARD_DEVIATION 11.38 • n=206 Participants
63.5 years
STANDARD_DEVIATION 11.65 • n=7 Participants
Sex: Female, Male
Female
30 Participants
n=99 Participants
40 Participants
n=107 Participants
38 Participants
n=206 Participants
108 Participants
n=7 Participants
Sex: Female, Male
Male
20 Participants
n=99 Participants
10 Participants
n=107 Participants
12 Participants
n=206 Participants
42 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
5 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
48 Participants
n=99 Participants
49 Participants
n=107 Participants
48 Participants
n=206 Participants
145 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
2 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
White
49 Participants
n=99 Participants
48 Participants
n=107 Participants
48 Participants
n=206 Participants
145 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
1 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

Population: ITT Population with the Markov Chain Monte Carlo (MCMC) imputation method for missing values.

It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)
Day 1 Pre-CAE
1.94 score on a scale
Standard Deviation 0.512
1.96 score on a scale
Standard Deviation 0.450
1.95 score on a scale
Standard Deviation 0.433
Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)
Change From Baseline to Day 57 (pre-CAE)
0.10 score on a scale
Standard Deviation 0.699
0.10 score on a scale
Standard Deviation 0.490
-0.02 score on a scale
Standard Deviation 0.631

PRIMARY outcome

Timeframe: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

Population: ITT Population with the MCMC imputation method for missing values.

It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
Day 1 Pre-CAE
2.6 score on a scale
Standard Deviation 0.86
2.5 score on a scale
Standard Deviation 0.95
2.4 score on a scale
Standard Deviation 0.75
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
Change from Baseline: Day 57 (Pre-CAE)
-0.5 score on a scale
Standard Deviation 1.16
-0.4 score on a scale
Standard Deviation 1.33
-0.1 score on a scale
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 Post-CAE
3.32 score on a scale
Standard Deviation 0.492
3.25 score on a scale
Standard Deviation 0.565
3.20 score on a scale
Standard Deviation 0.474
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
1.38 score on a scale
Standard Deviation 0.521
1.29 score on a scale
Standard Deviation 0.464
1.25 score on a scale
Standard Deviation 0.407
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.12 score on a scale
Standard Deviation 0.697
-0.20 score on a scale
Standard Deviation 0.608
-0.10 score on a scale
Standard Deviation 0.571
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.62 score on a scale
Standard Deviation 0.766
-0.85 score on a scale
Standard Deviation 0.736
-0.69 score on a scale
Standard Deviation 0.826
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 29 (Pre-CAE)
0.04 score on a scale
Standard Deviation 0.807
0.04 score on a scale
Standard Deviation 0.563
0.00 score on a scale
Standard Deviation 0.707
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 57 (Pre-CAE)
0.12 score on a scale
Standard Deviation 0.724
0.10 score on a scale
Standard Deviation 0.512
-0.02 score on a scale
Standard Deviation 0.631
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Day 1 Pre-CAE
1.94 score on a scale
Standard Deviation 0.512
1.96 score on a scale
Standard Deviation 0.450
1.95 score on a scale
Standard Deviation 0.443
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 8
0.19 score on a scale
Standard Deviation 0.706
-0.01 score on a scale
Standard Deviation 0.606
0.04 score on a scale
Standard Deviation 0.668
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.50 score on a scale
Standard Deviation 0.892
-0.66 score on a scale
Standard Deviation 0.793
-0.59 score on a scale
Standard Deviation 0.867
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.41 score on a scale
Standard Deviation 0.656
-0.83 score on a scale
Standard Deviation 0.677
-0.48 score on a scale
Standard Deviation 0.569
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.66 score on a scale
Standard Deviation 0.857
-1.02 score on a scale
Standard Deviation 0.624
-0.64 score on a scale
Standard Deviation 0.591
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.47 score on a scale
Standard Deviation 0.670
-0.84 score on a scale
Standard Deviation 0.738
-0.63 score on a scale
Standard Deviation 0.610
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.59 score on a scale
Standard Deviation 0.878
-0.92 score on a scale
Standard Deviation 0.663
-0.62 score on a scale
Standard Deviation 0.747

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the superior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.64 score on a scale
Standard Deviation 0.598
0.48 score on a scale
Standard Deviation 0.622
0.42 score on a scale
Standard Deviation 0.650
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.27 score on a scale
Standard Deviation 0.709
-0.25 score on a scale
Standard Deviation 0.555
-0.10 score on a scale
Standard Deviation 0.707
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 Pre-CAE
2.05 score on a scale
Standard Deviation 0.420
2.08 score on a scale
Standard Deviation 0.444
2.03 score on a scale
Standard Deviation 0.456
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Day 1 Post-CAE
2.69 score on a scale
Standard Deviation 0.552
2.56 score on a scale
Standard Deviation 0.559
2.45 score on a scale
Standard Deviation 0.556
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 8
-0.09 score on a scale
Standard Deviation 0.586
-0.27 score on a scale
Standard Deviation 0.592
-0.09 score on a scale
Standard Deviation 0.556
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.22 score on a scale
Standard Deviation 0.790
-0.45 score on a scale
Standard Deviation 0.724
-0.29 score on a scale
Standard Deviation 0.615
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.66 score on a scale
Standard Deviation 0.976
-0.72 score on a scale
Standard Deviation 0.798
-0.34 score on a scale
Standard Deviation 0.658
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.44 score on a scale
Standard Deviation 0.884
-0.27 score on a scale
Standard Deviation 0.743
-0.05 score on a scale
Standard Deviation 0.791
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.50 score on a scale
Standard Deviation 0.655
-0.65 score on a scale
Standard Deviation 0.822
-0.07 score on a scale
Standard Deviation 0.604
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.41 score on a scale
Standard Deviation 0.791
-0.52 score on a scale
Standard Deviation 0.964
-0.09 score on a scale
Standard Deviation 0.782
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.09 score on a scale
Standard Deviation 0.571
-0.14 score on a scale
Standard Deviation 0.594
-0.19 score on a scale
Standard Deviation 0.713
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.46 score on a scale
Standard Deviation 0.665
-0.37 score on a scale
Standard Deviation 0.787
-0.23 score on a scale
Standard Deviation 0.662
Mean Change From Baseline in Fluorescein Staining (Superior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.37 score on a scale
Standard Deviation 0.806
-0.21 score on a scale
Standard Deviation 0.847
-0.08 score on a scale
Standard Deviation 0.915

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the central region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 Post-CAE
2.22 score on a scale
Standard Deviation 0.624
2.09 score on a scale
Standard Deviation 0.550
2.04 score on a scale
Standard Deviation 0.676
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.52 score on a scale
Standard Deviation 0.963
-0.34 score on a scale
Standard Deviation 0.923
-0.33 score on a scale
Standard Deviation 0.956
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 29 (Pre-CAE)
0.01 score on a scale
Standard Deviation 0.906
-0.21 score on a scale
Standard Deviation 0.771
-0.07 score on a scale
Standard Deviation 0.776
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 Pre-CAE
1.45 score on a scale
Standard Deviation 0.687
1.57 score on a scale
Standard Deviation 0.670
1.49 score on a scale
Standard Deviation 0.610
Mean Change From Baseline in Fluorescein Staining (Central Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.77 score on a scale
Standard Deviation 0.641
0.052 score on a scale
Standard Deviation 0.735
0.55 score on a scale
Standard Deviation 0.633
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 8
0.12 score on a scale
Standard Deviation 0.766
-0.02 score on a scale
Standard Deviation 0.887
-0.05 score on a scale
Standard Deviation 0.779
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 15 (Pre-CAE)
0.00 score on a scale
Standard Deviation 0.869
-0.24 score on a scale
Standard Deviation 0.831
-0.09 score on a scale
Standard Deviation 0.780
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 15 (Post-CAE)
-0.52 score on a scale
Standard Deviation 0.749
-0.58 score on a scale
Standard Deviation 0.732
-0.42 score on a scale
Standard Deviation 0.724
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 29 (Post-CAE)
-0.50 score on a scale
Standard Deviation 0.612
-0.54 score on a scale
Standard Deviation 0.528
-0.16 score on a scale
Standard Deviation 0.653
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.69 score on a scale
Standard Deviation 0.870
-0.54 score on a scale
Standard Deviation 0.948
-0.20 score on a scale
Standard Deviation 0.916
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 57 (Pre-CAE)
0.00 score on a scale
Standard Deviation 0.837
-0.10 score on a scale
Standard Deviation 0.832
-0.20 score on a scale
Standard Deviation 0.802
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from Baseline: Day 57 (Post-CAE)
-0.36 score on a scale
Standard Deviation 0.765
-0.35 score on a scale
Standard Deviation 0.856
-0.30 score on a scale
Standard Deviation 0.847
Mean Change From Baseline in Fluorescein Staining (Central Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.36 score on a scale
Standard Deviation 1.089
-0.23 score on a scale
Standard Deviation 1.043
-0.13 score on a scale
Standard Deviation 0.846

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the temporal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.49 score on a scale
Standard Deviation 0.739
-0.54 score on a scale
Standard Deviation 0.683
-0.54 score on a scale
Standard Deviation 0.552
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.19 score on a scale
Standard Deviation 0.706
-0.18 score on a scale
Standard Deviation 0.828
-0.10 score on a scale
Standard Deviation 0.714
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.34 score on a scale
Standard Deviation 0.569
-0.38 score on a scale
Standard Deviation 0.653
-0.20 score on a scale
Standard Deviation 0.478
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.07 score on a scale
Standard Deviation 0.554
0.06 score on a scale
Standard Deviation 0.749
-0.09 score on a scale
Standard Deviation 0.754
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.30 score on a scale
Standard Deviation 0.679
-0.24 score on a scale
Standard Deviation 0.767
-0.33 score on a scale
Standard Deviation 0.696
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 Pre-CAE
2.14 score on a scale
Standard Deviation 0.452
2.12 score on a scale
Standard Deviation 0.521
2.02 score on a scale
Standard Deviation 0.622
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 Post-CAE
2.60 score on a scale
Standard Deviation 0.606
2.42 score on a scale
Standard Deviation 0.538
2.47 score on a scale
Standard Deviation 0.519
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.46 score on a scale
Standard Deviation 0.523
0.30 score on a scale
Standard Deviation 0.647
0.45 score on a scale
Standard Deviation 0.625
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 8
-0.01 score on a scale
Standard Deviation 0.520
-0.09 score on a scale
Standard Deviation 0.598
-0.13 score on a scale
Standard Deviation 0.755
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.34 score on a scale
Standard Deviation 0.601
-0.31 score on a scale
Standard Deviation 0.741
-0.14 score on a scale
Standard Deviation 0.736
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.15 score on a scale
Standard Deviation 0.835
-0.23 score on a scale
Standard Deviation 0.765
-0.40 score on a scale
Standard Deviation 0.857
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.26 score on a scale
Standard Deviation 0.872
-0.33 score on a scale
Standard Deviation 0.894
-0.20 score on a scale
Standard Deviation 0.737
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.24 score on a scale
Standard Deviation 0.842
-0.28 score on a scale
Standard Deviation 0.902
-0.26 score on a scale
Standard Deviation 0.824

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the nasal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 Pre-CAE
2.27 score on a scale
Standard Deviation 0.507
2.26 score on a scale
Standard Deviation 0.527
2.14 score on a scale
Standard Deviation 0.544
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.28 score on a scale
Standard Deviation 0.743
-0.29 score on a scale
Standard Deviation 0.600
-0.06 score on a scale
Standard Deviation 0.620
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.44 score on a scale
Standard Deviation 0.697
-0.52 score on a scale
Standard Deviation 0.785
-0.51 score on a scale
Standard Deviation 0.773
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.17 score on a scale
Standard Deviation 0.658
-0.19 score on a scale
Standard Deviation 0.694
-0.20 score on a scale
Standard Deviation 0.643
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.29 score on a scale
Standard Deviation 0.671
-0.26 score on a scale
Standard Deviation 0.960
-0.38 score on a scale
Standard Deviation 0.718
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 Post-CAE
2.74 score on a scale
Standard Deviation 0.649
2.67 score on a scale
Standard Deviation 0.577
2.68 score on a scale
Standard Deviation 0.587
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.47 score on a scale
Standard Deviation 0.557
0.41 score on a scale
Standard Deviation 0.541
0.54 score on a scale
Standard Deviation 0.638
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 8
-0.06 score on a scale
Standard Deviation 0.501
-0.05 score on a scale
Standard Deviation 0.518
-0.05 score on a scale
Standard Deviation 0.702
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.16 score on a scale
Standard Deviation 0.830
-0.23 score on a scale
Standard Deviation 0.772
-0.45 score on a scale
Standard Deviation 0.859
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.20 score on a scale
Standard Deviation 0.735
-0.18 score on a scale
Standard Deviation 0.688
-0.04 score on a scale
Standard Deviation 0.783
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.03 score on a scale
Standard Deviation 0.755
-0.06 score on a scale
Standard Deviation 0.589
-0.17 score on a scale
Standard Deviation 0.877
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.01 score on a scale
Standard Deviation 0.771
0.01 score on a scale
Standard Deviation 0.678
-0.24 score on a scale
Standard Deviation 0.600
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.28 score on a scale
Standard Deviation 0.696
-0.27 score on a scale
Standard Deviation 0.928
-0.15 score on a scale
Standard Deviation 0.805

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 Pre-CAE
5.44 score on a scale
Standard Deviation 1.232
5.61 score on a scale
Standard Deviation 1.230
5.47 score on a scale
Standard Deviation 1.154
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 8
0.22 score on a scale
Standard Deviation 1.559
-0.30 score on a scale
Standard Deviation 1.584
-0.10 score on a scale
Standard Deviation 1.544
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 Post-CAE
8.23 score on a scale
Standard Deviation 1.318
7.90 score on a scale
Standard Deviation 1.241
7.69 score on a scale
Standard Deviation 1.340
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
2.79 score on a scale
Standard Deviation 1.258
2.29 score on a scale
Standard Deviation 1.246
2.22 score on a scale
Standard Deviation 1.135
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.34 score on a scale
Standard Deviation 1.939
-0.89 score on a scale
Standard Deviation 1.562
-0.48 score on a scale
Standard Deviation 1.474
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 15 (Post-CAE)
-1.80 score on a scale
Standard Deviation 2.058
-2.16 score on a scale
Standard Deviation 1.695
-1.45 score on a scale
Standard Deviation 1.526
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-1.46 score on a scale
Standard Deviation 1.935
-1.27 score on a scale
Standard Deviation 1.516
-0.97 score on a scale
Standard Deviation 1.739
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.22 score on a scale
Standard Deviation 1.995
-0.42 score on a scale
Standard Deviation 1.404
-0.17 score on a scale
Standard Deviation 1.704
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 29 (Post-CAE)
-1.41 score on a scale
Standard Deviation 1.389
-2.02 score on a scale
Standard Deviation 1.360
-0.71 score on a scale
Standard Deviation 1.205
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-1.76 score on a scale
Standard Deviation 1.850
-2.08 score on a scale
Standard Deviation 1.659
-0.93 score on a scale
Standard Deviation 1.438
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 57 (Pre-CAE)
0.03 score on a scale
Standard Deviation 1.470
-0.14 score on a scale
Standard Deviation 1.579
-0.41 score on a scale
Standard Deviation 1.634
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from Baseline: Day 57 (Post-CAE)
-1.28 score on a scale
Standard Deviation 1.618
-1.56 score on a scale
Standard Deviation 1.780
-1.16 score on a scale
Standard Deviation 1.748
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-1.32 score on a scale
Standard Deviation 2.034
-1.36 score on a scale
Standard Deviation 1.881
-0.84 score on a scale
Standard Deviation 1.801

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Conjunctival sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.39 score on a scale
Standard Deviation 1.263
-0.35 score on a scale
Standard Deviation 1.360
-0.14 score on a scale
Standard Deviation 1.327
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.60 score on a scale
Standard Deviation 1.177
-0.50 score on a scale
Standard Deviation 1.528
-0.70 score on a scale
Standard Deviation 1.194
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 Pre-CAE
4.41 score on a scale
Standard Deviation 0.879
4.38 score on a scale
Standard Deviation 0.923
4.16 score on a scale
Standard Deviation 1.052
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 Post-CAE
5.34 score on a scale
Standard Deviation 1.118
5.09 score on a scale
Standard Deviation 0.941
5.15 score on a scale
Standard Deviation 0.981
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.93 score on a scale
Standard Deviation 0.827
0.71 score on a scale
Standard Deviation 0.964
0.99 score on a scale
Standard Deviation 1.095
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 8
-0.07 score on a scale
Standard Deviation 0.845
-0.15 score on a scale
Standard Deviation 0.875
-0.18 score on a scale
Standard Deviation 1.349
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.62 score on a scale
Standard Deviation 1.167
-0.60 score on a scale
Standard Deviation 1.158
-0.20 score on a scale
Standard Deviation 1.143
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 15 (Post-CAE)
-0.93 score on a scale
Standard Deviation 1.212
-1.06 score on a scale
Standard Deviation 1.295
-1.05 score on a scale
Standard Deviation 1.135
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.31 score on a scale
Standard Deviation 1.269
-0.46 score on a scale
Standard Deviation 1.258
-0.85 score on a scale
Standard Deviation 1.440
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.52 score on a scale
Standard Deviation 0.986
-0.58 score on a scale
Standard Deviation 1.206
-0.39 score on a scale
Standard Deviation 0.927
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.29 score on a scale
Standard Deviation 1.379
-0.38 score on a scale
Standard Deviation 1.219
-0.37 score on a scale
Standard Deviation 1.377
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.08 score on a scale
Standard Deviation 1.178
0.07 score on a scale
Standard Deviation 1.269
-0.33 score on a scale
Standard Deviation 1.223
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.52 score on a scale
Standard Deviation 1.273
-0.55 score on a scale
Standard Deviation 1.573
-0.41 score on a scale
Standard Deviation 1.306

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Post-CAE)
-1.93 score on a scale
Standard Deviation 1.831
-2.60 score on a scale
Standard Deviation 2.168
-1.11 score on a scale
Standard Deviation 1.739
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-2.05 score on a scale
Standard Deviation 2.530
-2.46 score on a scale
Standard Deviation 2.054
-1.30 score on a scale
Standard Deviation 2.403
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Pre-CAE
9.85 score on a scale
Standard Deviation 1.852
9.99 score on a scale
Standard Deviation 1.777
9.63 score on a scale
Standard Deviation 1.982
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Post-CAE
13.57 score on a scale
Standard Deviation 2.143
12.99 score on a scale
Standard Deviation 1.828
12.84 score on a scale
Standard Deviation 1.872
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 (Change from Pre-CAE to Post-CAE)
3.72 score on a scale
Standard Deviation 1.614
3.00 score on a scale
Standard Deviation 1.684
3.21 score on a scale
Standard Deviation 1.890
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 8
0.15 score on a scale
Standard Deviation 2.139
-0.45 score on a scale
Standard Deviation 2.009
-0.29 score on a scale
Standard Deviation 2.667
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Pre-CAE)
-0.96 score on a scale
Standard Deviation 2.866
-1.49 score on a scale
Standard Deviation 2.312
-0.68 score on a scale
Standard Deviation 2.338
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Post-CAE)
-2.73 score on a scale
Standard Deviation 2.875
-3.22 score on a scale
Standard Deviation 2.664
-2.50 score on a scale
Standard Deviation 2.150
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-1.77 score on a scale
Standard Deviation 2.686
-1.73 score on a scale
Standard Deviation 2.245
-1.82 score on a scale
Standard Deviation 2.676
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Pre-CAE)
-0.61 score on a scale
Standard Deviation 2.933
-0.77 score on a scale
Standard Deviation 2.214
-0.30 score on a scale
Standard Deviation 2.710
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Pre-CAE)
-0.04 score on a scale
Standard Deviation 2.250
-0.07 score on a scale
Standard Deviation 2.403
-0.74 score on a scale
Standard Deviation 2.560
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Post-CAE)
-1.88 score on a scale
Standard Deviation 2.400
-2.06 score on a scale
Standard Deviation 2.990
-1.87 score on a scale
Standard Deviation 2.559
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-1.84 score on a scale
Standard Deviation 2.763
-1.91 score on a scale
Standard Deviation 2.922
-1.24 score on a scale
Standard Deviation 2.387

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 8
0.04 score on a scale
Standard Deviation 0.699
-0.30 score on a scale
Standard Deviation 0.642
-0.08 score on a scale
Standard Deviation 0.702
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Day 1 Pre-CAE
1.42 score on a scale
Standard Deviation 0.642
1.46 score on a scale
Standard Deviation 0.605
1.50 score on a scale
Standard Deviation 0.580
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Day 1 Post-CAE
2.00 score on a scale
Standard Deviation 0.920
2.12 score on a scale
Standard Deviation 0.895
1.87 score on a scale
Standard Deviation 0.826
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.58 score on a scale
Standard Deviation 0.752
0.66 score on a scale
Standard Deviation 0.934
0.37 score on a scale
Standard Deviation 0.850
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.34 score on a scale
Standard Deviation 0.805
-0.43 score on a scale
Standard Deviation 0.644
-0.48 score on a scale
Standard Deviation 0.707
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.46 score on a scale
Standard Deviation 1.228
-0.76 score on a scale
Standard Deviation 0.984
-0.34 score on a scale
Standard Deviation 1.104
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.12 score on a scale
Standard Deviation 0.982
-0.33 score on a scale
Standard Deviation 0.919
0.14 score on a scale
Standard Deviation 1.170
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.14 score on a scale
Standard Deviation 0.815
-0.24 score on a scale
Standard Deviation 0.715
-0.28 score on a scale
Standard Deviation 0.607
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.10 score on a scale
Standard Deviation 1.191
-0.69 score on a scale
Standard Deviation 0.895
-0.20 score on a scale
Standard Deviation 1.074
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.10 score on a scale
Standard Deviation 1.064
-0.60 score on a scale
Standard Deviation 0.949
0.16 score on a scale
Standard Deviation 1.147
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.21 score on a scale
Standard Deviation 0.637
-0.17 score on a scale
Standard Deviation 0.869
-0.34 score on a scale
Standard Deviation 0.688
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.16 score on a scale
Standard Deviation 0.943
-0.60 score on a scale
Standard Deviation 0.877
-0.22 score on a scale
Standard Deviation 0.764
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.04 score on a scale
Standard Deviation 0.881
-0.38 score on a scale
Standard Deviation 1.179
0.07 score on a scale
Standard Deviation 0.866

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Day 1 Pre-CAE
1.22 score on a scale
Standard Deviation 0.507
1.32 score on a scale
Standard Deviation 0.560
1.27 score on a scale
Standard Deviation 0.546
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 8
-0.14 score on a scale
Standard Deviation 0.525
-0.31 score on a scale
Standard Deviation 0.624
-0.18 score on a scale
Standard Deviation 0.537
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.11 score on a scale
Standard Deviation 0.841
-0.08 score on a scale
Standard Deviation 0.808
0.04 score on a scale
Standard Deviation 0.936
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.29 score on a scale
Standard Deviation 0.729
-0.33 score on a scale
Standard Deviation 0.604
-0.44 score on a scale
Standard Deviation 0.712
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 29 (Post-CAE)
-0.19 score on a scale
Standard Deviation 0.806
-0.31 score on a scale
Standard Deviation 0.849
0.02 score on a scale
Standard Deviation 0.713
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.14 score on a scale
Standard Deviation 0.789
-0.04 score on a scale
Standard Deviation 0.916
0.30 score on a scale
Standard Deviation 0.896
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.32 score on a scale
Standard Deviation 0.541
-0.36 score on a scale
Standard Deviation 0.694
-0.40 score on a scale
Standard Deviation 0.769
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 57 (Post-CAE)
-0.37 score on a scale
Standard Deviation 0.679
-0.44 score on a scale
Standard Deviation 0.717
-0.28 score on a scale
Standard Deviation 0.736
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.05 score on a scale
Standard Deviation 0.797
-0.05 score on a scale
Standard Deviation 0.762
0.08 score on a scale
Standard Deviation 0.915
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Day 1 Post-CAE
1.48 score on a scale
Standard Deviation 0.580
1.51 score on a scale
Standard Deviation 0.703
1.44 score on a scale
Standard Deviation 0.697
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.26 score on a scale
Standard Deviation 0.527
0.19 score on a scale
Standard Deviation 0.669
0.17 score on a scale
Standard Deviation 0.760
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.37 score on a scale
Standard Deviation 0.838
-0.57 score on a scale
Standard Deviation 0.772
-0.38 score on a scale
Standard Deviation 0.907
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
Change from Baseline: Day 15 (Post-CAE)
-0.48 score on a scale
Standard Deviation 0.931
-0.66 score on a scale
Standard Deviation 0.870
-0.34 score on a scale
Standard Deviation 0.866

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 8
-0.13 score on a scale
Standard Deviation 0.676
-0.29 score on a scale
Standard Deviation 0.582
-0.24 score on a scale
Standard Deviation 0.723
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.13 score on a scale
Standard Deviation 0.720
-0.26 score on a scale
Standard Deviation 0.636
-0.24 score on a scale
Standard Deviation 0.744
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Day 1 Pre-CAE
0.48 score on a scale
Standard Deviation 0.735
0.57 score on a scale
Standard Deviation 0.742
0.54 score on a scale
Standard Deviation 0.734
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Day 1 Post-CAE
0.59 score on a scale
Standard Deviation 0.780
0.60 score on a scale
Standard Deviation 0.735
0.66 score on a scale
Standard Deviation 0.823
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.11 score on a scale
Standard Deviation 0.547
0.03 score on a scale
Standard Deviation 0.519
0.12 score on a scale
Standard Deviation 0.799
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 15 (Post-CAE)
-0.33 score on a scale
Standard Deviation 0.636
-0.29 score on a scale
Standard Deviation 0.706
-0.30 score on a scale
Standard Deviation 0.647
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.20 score on a scale
Standard Deviation 0.776
-0.03 score on a scale
Standard Deviation 0.815
-0.06 score on a scale
Standard Deviation 0.935
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.31 score on a scale
Standard Deviation 0.630
-0.22 score on a scale
Standard Deviation 0.837
-0.28 score on a scale
Standard Deviation 0.730
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.03 score on a scale
Standard Deviation 0.680
-0.17 score on a scale
Standard Deviation 0.677
0.11 score on a scale
Standard Deviation 0.956
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.23 score on a scale
Standard Deviation 0.555
-0.31 score on a scale
Standard Deviation 0.667
-0.16 score on a scale
Standard Deviation 0.681
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 57 (Post-CAE)
-0.14 score on a scale
Standard Deviation 0.602
-0.34 score on a scale
Standard Deviation 0.898
-0.31 score on a scale
Standard Deviation 0.619
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.09 score on a scale
Standard Deviation 0.652
-0.02 score on a scale
Standard Deviation 0.879
-0.18 score on a scale
Standard Deviation 0.782
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
Change from Baseline: Day 29 (Post-CAE)
-0.07 score on a scale
Standard Deviation 0.258
-0.15 score on a scale
Standard Deviation 0.660
-0.07 score on a scale
Standard Deviation 0.466

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.26 score on a scale
Standard Deviation 0.721
-0.20 score on a scale
Standard Deviation 0.816
-0.16 score on a scale
Standard Deviation 0.710
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Day 1 Pre-CAE
1.63 score on a scale
Standard Deviation 0.706
1.63 score on a scale
Standard Deviation 0.669
1.61 score on a scale
Standard Deviation 0.751
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Day 1 Post-CAE
1.87 score on a scale
Standard Deviation 0.691
1.71 score on a scale
Standard Deviation 0.671
1.87 score on a scale
Standard Deviation 0.734
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.24 score on a scale
Standard Deviation 0.649
0.08 score on a scale
Standard Deviation 0.695
0.26 score on a scale
Standard Deviation 0.834
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 8
-0.09 score on a scale
Standard Deviation 0.733
-0.11 score on a scale
Standard Deviation 0.864
-0.15 score on a scale
Standard Deviation 0.686
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.32 score on a scale
Standard Deviation 0.885
-0.48 score on a scale
Standard Deviation 0.707
-0.46 score on a scale
Standard Deviation 0.885
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.05 score on a scale
Standard Deviation 1.029
0.03 score on a scale
Standard Deviation 0.947
-0.07 score on a scale
Standard Deviation 1.066
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.37 score on a scale
Standard Deviation 0.669
-0.50 score on a scale
Standard Deviation 0.772
-0.50 score on a scale
Standard Deviation 0.606
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.05 score on a scale
Standard Deviation 0.876
-0.02 score on a scale
Standard Deviation 0.928
-0.04 score on a scale
Standard Deviation 0.919
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.29 score on a scale
Standard Deviation 0.915
-0.21 score on a scale
Standard Deviation 0.683
-0.19 score on a scale
Standard Deviation 0.630
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.28 score on a scale
Standard Deviation 0.663
-0.06 score on a scale
Standard Deviation 0.668
-0.25 score on a scale
Standard Deviation 0.569
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.09 score on a scale
Standard Deviation 1.142
0.08 score on a scale
Standard Deviation 0.688
-0.05 score on a scale
Standard Deviation 0.916
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.21 score on a scale
Standard Deviation 0.750
-0.22 score on a scale
Standard Deviation 0.934
-0.22 score on a scale
Standard Deviation 0.715

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Day 1 Post-CAE
2.18 score on a scale
Standard Deviation 0.774
2.05 score on a scale
Standard Deviation 0.828
1.93 score on a scale
Standard Deviation 0.693
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 8
-0.04 score on a scale
Standard Deviation 0.748
-0.25 score on a scale
Standard Deviation 0.668
0.00 score on a scale
Standard Deviation 0.677
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 15 (Post-CAE)
-0.23 score on a scale
Standard Deviation 0.858
-0.29 score on a scale
Standard Deviation 0.904
-0.24 score on a scale
Standard Deviation 0.672
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.09 score on a scale
Standard Deviation 0.780
0.52 score on a scale
Standard Deviation 0.781
-0.02 score on a scale
Standard Deviation 1.004
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 57 (Pre-CAE)
-0.12 score on a scale
Standard Deviation 0.709
-0.31 score on a scale
Standard Deviation 0.692
-0.10 score on a scale
Standard Deviation 0.721
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 57 (Post-CAE)
-0.26 score on a scale
Standard Deviation 0.815
-0.16 score on a scale
Standard Deviation 0.843
-0.02 score on a scale
Standard Deviation 0.841
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.14 score on a scale
Standard Deviation 0.821
0.17 score on a scale
Standard Deviation 0.872
0.05 score on a scale
Standard Deviation 0.959
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Day 1 Pre-CAE
1.90 score on a scale
Standard Deviation 0.707
1.96 score on a scale
Standard Deviation 0.561
1.69 score on a scale
Standard Deviation 0.638
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Day 1 (Change from Pre-CAE to Post-CAE)
0.28 score on a scale
Standard Deviation 0.640
0.09 score on a scale
Standard Deviation 0.740
0.24 score on a scale
Standard Deviation 0.816
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 15 (Pre-CAE)
-0.22 score on a scale
Standard Deviation 0.723
-0.48 score on a scale
Standard Deviation 0.660
-0.23 score on a scale
Standard Deviation 0.822
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 0.901
0.19 score on a scale
Standard Deviation 1.070
-0.01 score on a scale
Standard Deviation 1.013
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 29 (Pre-CAE)
-0.28 score on a scale
Standard Deviation 0.679
-0.39 score on a scale
Standard Deviation 0.638
-0.03 score on a scale
Standard Deviation 0.785
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
Change from Baseline: Day 29 (Post-CAE)
-0.19 score on a scale
Standard Deviation 0.737
0.10 score on a scale
Standard Deviation 0.749
-0.11 score on a scale
Standard Deviation 0.854

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.84 score on a scale
Standard Deviation 1.633
-1.26 score on a scale
Standard Deviation 1.568
-1.10 score on a scale
Standard Deviation 1.909
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 15 (Post-CAE)
-1.27 score on a scale
Standard Deviation 2.264
-1.71 score on a scale
Standard Deviation 2.118
-0.98 score on a scale
Standard Deviation 1.924
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.21 score on a scale
Standard Deviation 1.578
-0.81 score on a scale
Standard Deviation 1.588
0.57 score on a scale
Standard Deviation 1.783
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.67 score on a scale
Standard Deviation 1.674
-1.38 score on a scale
Standard Deviation 1.936
-0.81 score on a scale
Standard Deviation 1.439
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Day 1 Pre-CAE
3.12 score on a scale
Standard Deviation 1.272
3.35 score on a scale
Standard Deviation 1.360
3.31 score on a scale
Standard Deviation 1.344
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Day 1 Post-CAE
4.07 score on a scale
Standard Deviation 1.705
4.23 score on a scale
Standard Deviation 1.785
3.97 score on a scale
Standard Deviation 1.828
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.95 score on a scale
Standard Deviation 1.314
0.88 score on a scale
Standard Deviation 1.683
0.66 score on a scale
Standard Deviation 1.701
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 8
-0.23 score on a scale
Standard Deviation 1.258
-0.91 score on a scale
Standard Deviation 1.382
-0.51 score on a scale
Standard Deviation 1.375
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.43 score on a scale
Standard Deviation 1.648
-0.45 score on a scale
Standard Deviation 1.952
0.12 score on a scale
Standard Deviation 1.965
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.74 score on a scale
Standard Deviation 1.516
-0.79 score on a scale
Standard Deviation 1.487
-1.00 score on a scale
Standard Deviation 1.488
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.36 score on a scale
Standard Deviation 1.782
-1.15 score on a scale
Standard Deviation 1.754
-0.25 score on a scale
Standard Deviation 1.430
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.75 score on a scale
Standard Deviation 1.228
-0.84 score on a scale
Standard Deviation 1.751
-0.90 score on a scale
Standard Deviation 1.793
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.08 score on a scale
Standard Deviation 1.494
-0.45 score on a scale
Standard Deviation 2.154
-0.03 score on a scale
Standard Deviation 1.586

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 29 (Post-CAE)
-0.47 score on a scale
Standard Deviation 1.195
0.04 score on a scale
Standard Deviation 1.264
-0.36 score on a scale
Standard Deviation 1.154
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.00 score on a scale
Standard Deviation 1.553
0.60 score on a scale
Standard Deviation 1.200
-0.07 score on a scale
Standard Deviation 1.412
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 57 (Pre-CAE)
-0.38 score on a scale
Standard Deviation 1.175
-0.51 score on a scale
Standard Deviation 1.349
-0.26 score on a scale
Standard Deviation 1.222
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 57 (Post-CAE)
-0.47 score on a scale
Standard Deviation 1.356
-0.38 score on a scale
Standard Deviation 1.577
-0.24 score on a scale
Standard Deviation 1.377
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.09 score on a scale
Standard Deviation 1.668
0.21 score on a scale
Standard Deviation 1.461
-0.02 score on a scale
Standard Deviation 1.723
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Day 1 Pre-CAE
3.53 score on a scale
Standard Deviation 1.231
3.59 score on a scale
Standard Deviation 1.058
3.30 score on a scale
Standard Deviation 1.237
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Day 1 Post-CAE
4.05 score on a scale
Standard Deviation 1.314
3.76 score on a scale
Standard Deviation 1.322
3.80 score on a scale
Standard Deviation 1.262
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Day 1 (Change from Pre-CAE to Post-CAE)
0.52 score on a scale
Standard Deviation 1.092
0.17 score on a scale
Standard Deviation 1.223
0.50 score on a scale
Standard Deviation 1.403
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 8
-0.13 score on a scale
Standard Deviation 1.249
-0.36 score on a scale
Standard Deviation 1.197
-0.15 score on a scale
Standard Deviation 1.133
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 15 (Pre-CAE)
-0.54 score on a scale
Standard Deviation 1.417
-0.96 score on a scale
Standard Deviation 1.056
-0.69 score on a scale
Standard Deviation 1.548
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 15 (Post-CAE)
-0.60 score on a scale
Standard Deviation 1.245
-0.79 score on a scale
Standard Deviation 1.228
-0.74 score on a scale
Standard Deviation 1.084
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.06 score on a scale
Standard Deviation 1.427
0.17 score on a scale
Standard Deviation 1.524
-0.05 score on a scale
Standard Deviation 1.724
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Change from Baseline: Day 29 (Pre-CAE)
-0.57 score on a scale
Standard Deviation 1.336
-0.59 score on a scale
Standard Deviation 1.090
-0.22 score on a scale
Standard Deviation 1.112

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.21 score on a scale
Standard Deviation 2.551
-0.21 score on a scale
Standard Deviation 2.016
0.50 score on a scale
Standard Deviation 2.553
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Pre-CAE
6.65 score on a scale
Standard Deviation 2.277
6.94 score on a scale
Standard Deviation 2.091
6.61 score on a scale
Standard Deviation 2.223
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 Post-CAE
8.12 score on a scale
Standard Deviation 2.653
7.99 score on a scale
Standard Deviation 2.753
7.77 score on a scale
Standard Deviation 2.741
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Day 1 (Change from Pre-CAE to Post-CAE)
1.47 score on a scale
Standard Deviation 1.923
1.05 score on a scale
Standard Deviation 2.493
1.16 score on a scale
Standard Deviation 2.708
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 8
-0.36 score on a scale
Standard Deviation 2.124
-1.27 score on a scale
Standard Deviation 2.065
-0.66 score on a scale
Standard Deviation 2.090
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Pre-CAE)
-1.38 score on a scale
Standard Deviation 2.767
-2.22 score on a scale
Standard Deviation 2.193
-1.79 score on a scale
Standard Deviation 3.059
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 15 (Post-CAE)
-1.87 score on a scale
Standard Deviation 3.156
-2.50 score on a scale
Standard Deviation 2.836
-1.72 score on a scale
Standard Deviation 2.607
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.49 score on a scale
Standard Deviation 2.409
-0.28 score on a scale
Standard Deviation 2.633
0.07 score on a scale
Standard Deviation 3.161
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Pre-CAE)
-1.31 score on a scale
Standard Deviation 2.435
-1.39 score on a scale
Standard Deviation 2.038
-1.22 score on a scale
Standard Deviation 2.150
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 29 (Post-CAE)
-0.83 score on a scale
Standard Deviation 2.369
-1.12 score on a scale
Standard Deviation 2.455
-0.61 score on a scale
Standard Deviation 2.025
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Pre-CAE)
-1.13 score on a scale
Standard Deviation 1.815
-1.35 score on a scale
Standard Deviation 2.684
-1.16 score on a scale
Standard Deviation 2.616
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from Baseline: Day 57 (Post-CAE)
-1.14 score on a scale
Standard Deviation 2.635
-1.77 score on a scale
Standard Deviation 3.087
-1.05 score on a scale
Standard Deviation 2.424
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.01 score on a scale
Standard Deviation 2.568
-0.24 score on a scale
Standard Deviation 3.138
-0.05 score on a scale
Standard Deviation 2.716

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 15 (Pre-CAE)
0.386 seconds
Standard Deviation 0.8008
0.127 seconds
Standard Deviation 0.7945
0.276 seconds
Standard Deviation 0.7857
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.021 seconds
Standard Deviation 0.6113
0.063 seconds
Standard Deviation 0.8557
-0.003 seconds
Standard Deviation 0.6473
Change From Baseline in Tear Film Break-Up Time
Day 1 Pre-CAE
1.559 seconds
Standard Deviation 0.5031
1.709 seconds
Standard Deviation 0.7083
1.574 seconds
Standard Deviation 0.5394
Change From Baseline in Tear Film Break-Up Time
Day 1 Post-CAE
1.533 seconds
Standard Deviation 0.5217
1.555 seconds
Standard Deviation 0.5441
1.574 seconds
Standard Deviation 0.5322
Change From Baseline in Tear Film Break-Up Time
Day 1 (Change from Pre-CAE to Post-CAE)
-0.027 seconds
Standard Deviation 0.4552
-0.154 seconds
Standard Deviation 0.5516
-0.001 seconds
Standard Deviation 0.3670
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 8
0.024 seconds
Standard Deviation 0.4943
-0.037 seconds
Standard Deviation 0.7421
-0.036 seconds
Standard Deviation 0.4948
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 15 (Post-CAE)
0.312 seconds
Standard Deviation 0.9470
0.195 seconds
Standard Deviation 0.6835
0.222 seconds
Standard Deviation 0.7884
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.075 seconds
Standard Deviation 0.7355
0.068 seconds
Standard Deviation 0.6543
-0.054 seconds
Standard Deviation 0.6252
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 29 (Pre-CAE)
0.218 seconds
Standard Deviation 0.7586
-0.191 seconds
Standard Deviation 0.5936
-0.077 seconds
Standard Deviation 0.5228
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 29 (Post-CAE)
0.123 seconds
Standard Deviation 0.7116
0.086 seconds
Standard Deviation 0.6752
-0.188 seconds
Standard Deviation 0.3884
Change From Baseline in Tear Film Break-Up Time
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.054 seconds
Standard Deviation 0.5013
0.129 seconds
Standard Deviation 0.4258
-0.119 seconds
Standard Deviation 0.5623
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 57 (Pre-CAE)
0.139 seconds
Standard Deviation 0.5727
-0.036 seconds
Standard Deviation 0.8880
0.186 seconds
Standard Deviation 0.6696
Change From Baseline in Tear Film Break-Up Time
Change from Baseline: Day 57 (Post-CAE)
0.118 seconds
Standard Deviation 0.7072
0.039 seconds
Standard Deviation 0.6057
0.160 seconds
Standard Deviation 0.7206

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.06 score on a scale
Standard Deviation 0.983
-0.19 score on a scale
Standard Deviation 0.836
-0.03 score on a scale
Standard Deviation 0.785
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 29 (Pre-CAE)
-0.06 score on a scale
Standard Deviation 0.740
-0.03 score on a scale
Standard Deviation 0.614
-0.10 score on a scale
Standard Deviation 0.685
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 29 (Post-CAE)
-0.22 score on a scale
Standard Deviation 0.635
-0.31 score on a scale
Standard Deviation 0.601
-0.21 score on a scale
Standard Deviation 0.568
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 Pre-CAE
1.70 score on a scale
Standard Deviation 0.639
1.66 score on a scale
Standard Deviation 0.566
1.72 score on a scale
Standard Deviation 0.536
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 (Change from Pre-CAE to Post-CAE)
0.33 score on a scale
Standard Deviation 0.603
0.36 score on a scale
Standard Deviation 0.655
0.32 score on a scale
Standard Deviation 0.569
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 8
0.04 score on a scale
Standard Deviation 0.588
-0.07 score on a scale
Standard Deviation 0.473
0.00 score on a scale
Standard Deviation 0.669
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 15 (Pre-CAE)
-0.20 score on a scale
Standard Deviation 0.606
-0.17 score on a scale
Standard Deviation 0.559
-0.17 score on a scale
Standard Deviation 0.568
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 15 (Post-CAE)
-0.14 score on a scale
Standard Deviation 0.663
-0.35 score on a scale
Standard Deviation 0.515
-0.20 score on a scale
Standard Deviation 0.606
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Day 1 Post-CAE
2.03 score on a scale
Standard Deviation 0.626
2.02 score on a scale
Standard Deviation 0.571
2.04 score on a scale
Standard Deviation 0.523
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.05 score on a scale
Standard Deviation 0.967
-0.21 score on a scale
Standard Deviation 0.907
-0.11 score on a scale
Standard Deviation 1.012
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 57 (Pre-CAE)
0.01 score on a scale
Standard Deviation 0.563
0.23 score on a scale
Standard Deviation 0.660
0.11 score on a scale
Standard Deviation 0.565
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from Baseline: Day 57 (Post-CAE)
-0.03 score on a scale
Standard Deviation 0.591
-0.01 score on a scale
Standard Deviation 0.728
-0.14 score on a scale
Standard Deviation 0.586
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.04 score on a scale
Standard Deviation 0.788
-0.22 score on a scale
Standard Deviation 0.941
-0.28 score on a scale
Standard Deviation 0.708

SECONDARY outcome

Timeframe: Baseline (Day 1); Days 15, 29, and 57

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Subjects will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Schirmer's Test
Day 1
5.0 mm
Standard Deviation 2.60
5.2 mm
Standard Deviation 3.03
5.5 mm
Standard Deviation 3.02
Change From Baseline in Schirmer's Test
Change From Baseline: Day 15
1.7 mm
Standard Deviation 5.21
4.0 mm
Standard Deviation 7.36
3.4 mm
Standard Deviation 6.50
Change From Baseline in Schirmer's Test
Change From Baseline: Day 29
0.8 mm
Standard Deviation 5.01
0.9 mm
Standard Deviation 4.23
1.8 mm
Standard Deviation 4.35
Change From Baseline in Schirmer's Test
Change From Baseline: Day 57
3.5 mm
Standard Deviation 6.70
2.9 mm
Standard Deviation 4.74
3.3 mm
Standard Deviation 6.84

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Day 1 Post-CAE
3.8 score on a scale
Standard Deviation 0.52
3.7 score on a scale
Standard Deviation 0.47
3.8 score on a scale
Standard Deviation 0.52
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.3 score on a scale
Standard Deviation 1.30
0.4 score on a scale
Standard Deviation 1.43
-0.1 score on a scale
Standard Deviation 1.17
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Day 1 Pre-CAE
2.6 score on a scale
Standard Deviation 0.86
2.5 score on a scale
Standard Deviation 0.95
2.4 score on a scale
Standard Deviation 0.75
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Day 1 (Change from Pre-CAE to Post-CAE)
1.2 score on a scale
Standard Deviation 0.98
1.2 score on a scale
Standard Deviation 1.01
1.4 score on a scale
Standard Deviation 0.81
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 8
-0.5 score on a scale
Standard Deviation 0.89
0.1 score on a scale
Standard Deviation 0.81
-0.1 score on a scale
Standard Deviation 1.01
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 15 (Pre-CAE)
-0.5 score on a scale
Standard Deviation 0.71
-0.1 score on a scale
Standard Deviation 0.96
-0.1 score on a scale
Standard Deviation 0.87
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 15 (Post-CAE)
0.0 score on a scale
Standard Deviation 0.62
0.0 score on a scale
Standard Deviation 0.58
0.0 score on a scale
Standard Deviation 0.55
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.5 score on a scale
Standard Deviation 0.91
0.1 score on a scale
Standard Deviation 1.13
0.1 score on a scale
Standard Deviation 1.05
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 29 (Pre-CAE)
-0.4 score on a scale
Standard Deviation 1.03
-0.3 score on a scale
Standard Deviation 0.92
-0.2 score on a scale
Standard Deviation 1.05
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 29 (Post-CAE)
0.0 score on a scale
Standard Deviation 0.63
-0.2 score on a scale
Standard Deviation 0.63
0.0 score on a scale
Standard Deviation 0.88
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.5 score on a scale
Standard Deviation 1.18
0.0 score on a scale
Standard Deviation 1.11
0.1 score on a scale
Standard Deviation 1.36
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 57 (Pre-CAE)
-0.5 score on a scale
Standard Deviation 1.17
-0.4 score on a scale
Standard Deviation 1.39
-0.1 score on a scale
Standard Deviation 0.88
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
Change from Baseline: Day 57 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.77
-0.1 score on a scale
Standard Deviation 0.65
-0.2 score on a scale
Standard Deviation 0.76

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 29 (Pre-CAE)
-0.3 score on a scale
Standard Deviation 1.05
-0.3 score on a scale
Standard Deviation 1.19
-0.3 score on a scale
Standard Deviation 1.17
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 29 (Post-CAE)
-0.1 score on a scale
Standard Deviation 0.90
0.0 score on a scale
Standard Deviation 0.89
-0.1 score on a scale
Standard Deviation 0.72
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.3 score on a scale
Standard Deviation 1.03
0.3 score on a scale
Standard Deviation 1.23
0.2 score on a scale
Standard Deviation 1.49
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 57 (Pre-CAE)
-0.5 score on a scale
Standard Deviation 1.35
-0.4 score on a scale
Standard Deviation 1.35
-0.2 score on a scale
Standard Deviation 1.06
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 57 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.86
0.0 score on a scale
Standard Deviation 0.64
-0.4 score on a scale
Standard Deviation 0.98
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.3 score on a scale
Standard Deviation 1.47
0.5 score on a scale
Standard Deviation 1.32
-0.1 score on a scale
Standard Deviation 1.33
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 Pre-CAE
2.9 score on a scale
Standard Deviation 0.88
2.7 score on a scale
Standard Deviation 1.09
2.8 score on a scale
Standard Deviation 0.78
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 Post-CAE
3.8 score on a scale
Standard Deviation 0.57
3.7 score on a scale
Standard Deviation 0.81
4.0 score on a scale
Standard Deviation 0.74
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Day 1 (Change from Pre-CAE to Post-CAE)
0.9 score on a scale
Standard Deviation 0.82
1.0 score on a scale
Standard Deviation 1.11
1.2 score on a scale
Standard Deviation 0.92
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 8
-0.3 score on a scale
Standard Deviation 0.97
0.0 score on a scale
Standard Deviation 0.98
-0.2 score on a scale
Standard Deviation 0.90
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 15 (Pre-CAE)
-0.4 score on a scale
Standard Deviation 0.93
0.0 score on a scale
Standard Deviation 1.00
-0.1 score on a scale
Standard Deviation 0.97
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from Baseline: Day 15 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.78
0.0 score on a scale
Standard Deviation 0.66
-0.2 score on a scale
Standard Deviation 0.95
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.2 score on a scale
Standard Deviation 1.13
0.0 score on a scale
Standard Deviation 1.07
0.0 score on a scale
Standard Deviation 1.40

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 Pre-CAE
1.6 score on a scale
Standard Deviation 1.31
1.4 score on a scale
Standard Deviation 1.35
1.2 score on a scale
Standard Deviation 1.28
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 15 (Post-CAE)
-0.1 score on a scale
Standard Deviation 1.16
0.0 score on a scale
Standard Deviation 1.17
-0.1 score on a scale
Standard Deviation 1.05
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.62
0.2 score on a scale
Standard Deviation 1.40
-0.1 score on a scale
Standard Deviation 1.40
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 Post-CAE
2.5 score on a scale
Standard Deviation 1.49
2.3 score on a scale
Standard Deviation 1.55
2.4 score on a scale
Standard Deviation 1.66
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Day 1 (Change from Pre-CAE to Post-CAE)
1.0 score on a scale
Standard Deviation 1.26
0.9 score on a scale
Standard Deviation 1.12
1.2 score on a scale
Standard Deviation 1.29
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 8
-0.1 score on a scale
Standard Deviation 0.81
0.0 score on a scale
Standard Deviation 0.92
0.0 score on a scale
Standard Deviation 0.85
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 15 (Pre-CAE)
-0.1 score on a scale
Standard Deviation 1.04
-0.2 score on a scale
Standard Deviation 1.14
0.0 score on a scale
Standard Deviation 0.74
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 29 (Pre-CAE)
-0.1 score on a scale
Standard Deviation 1.14
-0.2 score on a scale
Standard Deviation 1.18
0.0 score on a scale
Standard Deviation 0.84
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 29 (Post-CAE)
-0.1 score on a scale
Standard Deviation 1.35
-0.2 score on a scale
Standard Deviation 0.97
-0.1 score on a scale
Standard Deviation 0.85
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.1 score on a scale
Standard Deviation 1.25
0.4 score on a scale
Standard Deviation 1.24
-0.3 score on a scale
Standard Deviation 1.21
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 57 (Pre-CAE)
-0.1 score on a scale
Standard Deviation 1.22
-0.5 score on a scale
Standard Deviation 1.50
-0.1 score on a scale
Standard Deviation 0.93
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.1 score on a scale
Standard Deviation 1.48
0.5 score on a scale
Standard Deviation 1.26
-0.2 score on a scale
Standard Deviation 1.30
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Change from Baseline: Day 57 (Post-CAE)
-0.2 score on a scale
Standard Deviation 1.09
-0.1 score on a scale
Standard Deviation 1.28
-0.3 score on a scale
Standard Deviation 1.01

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 Pre-CAE
3.1 score on a scale
Standard Deviation 0.87
3.1 score on a scale
Standard Deviation 1.03
3.0 score on a scale
Standard Deviation 0.84
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 Post-CAE
4.0 score on a scale
Standard Deviation 0.71
3.9 score on a scale
Standard Deviation 0.80
4.1 score on a scale
Standard Deviation 0.63
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Day 1 (Change from Pre-CAE to Post-CAE)
1.0 score on a scale
Standard Deviation 0.86
0.9 score on a scale
Standard Deviation 0.76
1.1 score on a scale
Standard Deviation 0.99
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 8
-0.4 score on a scale
Standard Deviation 0.90
-0.1 score on a scale
Standard Deviation 0.70
-0.2 score on a scale
Standard Deviation 0.77
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 15 (Pre-CAE)
-0.3 score on a scale
Standard Deviation 0.80
-0.2 score on a scale
Standard Deviation 0.90
-0.1 score on a scale
Standard Deviation 0.76
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 15 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.71
-0.2 score on a scale
Standard Deviation 0.80
-0.1 score on a scale
Standard Deviation 0.95
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.1 score on a scale
Standard Deviation 1.08
0.0 score on a scale
Standard Deviation 0.98
0.0 score on a scale
Standard Deviation 1.29
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 29 (Pre-CAE)
-0.2 score on a scale
Standard Deviation 1.03
-0.4 score on a scale
Standard Deviation 1.01
-0.3 score on a scale
Standard Deviation 0.94
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 29 (Post-CAE)
-0.3 score on a scale
Standard Deviation 1.04
-0.2 score on a scale
Standard Deviation 0.67
-0.2 score on a scale
Standard Deviation 0.79
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 0.98
0.5 score on a scale
Standard Deviation 1.17
0.1 score on a scale
Standard Deviation 1.33
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 57 (Pre-CAE)
-0.4 score on a scale
Standard Deviation 1.25
-0.3 score on a scale
Standard Deviation 1.20
-0.2 score on a scale
Standard Deviation 1.08
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from Baseline: Day 57 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.85
-0.1 score on a scale
Standard Deviation 0.82
-0.3 score on a scale
Standard Deviation 1.09
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.1 score on a scale
Standard Deviation 1.31
0.3 score on a scale
Standard Deviation 1.04
-0.1 score on a scale
Standard Deviation 1.36

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 Pre-CAE
2.1 score on a scale
Standard Deviation 1.27
1.8 score on a scale
Standard Deviation 1.47
2.0 score on a scale
Standard Deviation 1.35
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 Post-CAE
2.7 score on a scale
Standard Deviation 1.40
2.3 score on a scale
Standard Deviation 1.63
3.0 score on a scale
Standard Deviation 1.28
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Day 1 (Change from Pre-CAE to Post-CAE)
0.7 score on a scale
Standard Deviation 1.10
0.5 score on a scale
Standard Deviation 0.96
1.1 score on a scale
Standard Deviation 1.10
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 8
-0.2 score on a scale
Standard Deviation 1.06
-0.1 score on a scale
Standard Deviation 0.67
0.1 score on a scale
Standard Deviation 0.95
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 15 (Pre-CAE)
-0.1 score on a scale
Standard Deviation 1.05
0.2 score on a scale
Standard Deviation 1.06
0.0 score on a scale
Standard Deviation 0.68
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 15 (Post-CAE)
-0.1 score on a scale
Standard Deviation 1.00
0.2 score on a scale
Standard Deviation 1.24
-0.3 score on a scale
Standard Deviation 1.07
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.29
0.0 score on a scale
Standard Deviation 1.03
-0.3 score on a scale
Standard Deviation 1.33
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 29 (Pre-CAE)
-0.2 score on a scale
Standard Deviation 1.25
-0.1 score on a scale
Standard Deviation 1.18
-0.2 score on a scale
Standard Deviation 1.04
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 29 (Post-CAE)
-0.2 score on a scale
Standard Deviation 0.99
0.1 score on a scale
Standard Deviation 1.03
-0.1 score on a scale
Standard Deviation 0.74
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.1 score on a scale
Standard Deviation 1.18
0.3 score on a scale
Standard Deviation 1.01
0.0 score on a scale
Standard Deviation 1.22
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 57 (Pre-CAE)
-0.4 score on a scale
Standard Deviation 1.20
-0.1 score on a scale
Standard Deviation 1.29
-0.1 score on a scale
Standard Deviation 0.94
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from Baseline: Day 57 (Post-CAE)
-0.3 score on a scale
Standard Deviation 1.06
0.2 score on a scale
Standard Deviation 1.13
-0.6 score on a scale
Standard Deviation 1.08
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.44
0.3 score on a scale
Standard Deviation 1.09
-0.4 score on a scale
Standard Deviation 1.14

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 Pre-CAE
1.5 score on a scale
Standard Deviation 1.33
1.2 score on a scale
Standard Deviation 1.35
1.0 score on a scale
Standard Deviation 1.08
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 Post-CAE
2.3 score on a scale
Standard Deviation 1.42
1.9 score on a scale
Standard Deviation 1.55
2.0 score on a scale
Standard Deviation 1.67
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Day 1 (Change from Pre-CAE to Post-CAE)
0.8 score on a scale
Standard Deviation 1.18
0.7 score on a scale
Standard Deviation 1.05
1.0 score on a scale
Standard Deviation 1.26
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 8
-0.3 score on a scale
Standard Deviation 0.92
-0.2 score on a scale
Standard Deviation 0.86
-0.1 score on a scale
Standard Deviation 0.69
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 15 (Pre-CAE)
-0.2 score on a scale
Standard Deviation 1.04
-0.2 score on a scale
Standard Deviation 1.08
0.0 score on a scale
Standard Deviation 0.76
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 15 (Post-CAE)
-0.3 score on a scale
Standard Deviation 1.12
0.0 score on a scale
Standard Deviation 1.00
-0.1 score on a scale
Standard Deviation 1.19
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.34
0.2 score on a scale
Standard Deviation 1.24
-0.1 score on a scale
Standard Deviation 1.41
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 29 (Pre-CAE)
-0.2 score on a scale
Standard Deviation 1.12
-0.3 score on a scale
Standard Deviation 1.03
-0.1 score on a scale
Standard Deviation 0.90
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 29 (Post-CAE)
-0.3 score on a scale
Standard Deviation 1.23
-0.4 score on a scale
Standard Deviation 1.06
-0.2 score on a scale
Standard Deviation 1.28
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.16
0.1 score on a scale
Standard Deviation 1.06
-0.2 score on a scale
Standard Deviation 1.47
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 57 (Pre-CAE)
-0.2 score on a scale
Standard Deviation 1.35
-0.3 score on a scale
Standard Deviation 1.40
-0.1 score on a scale
Standard Deviation 1.01
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from Baseline: Day 57 (Post-CAE)
-0.3 score on a scale
Standard Deviation 1.12
-0.1 score on a scale
Standard Deviation 1.28
-0.4 score on a scale
Standard Deviation 1.30
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.0 score on a scale
Standard Deviation 1.83
0.3 score on a scale
Standard Deviation 1.41
-0.3 score on a scale
Standard Deviation 1.51

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of burning by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Burning)
Day 1 Pre-CAE
30.4 mm
Standard Deviation 28.53
29.3 mm
Standard Deviation 26.74
22.4 mm
Standard Deviation 24.60
Change From Baseline in Visual Analog Scale (Burning)
Day 1 Post-CAE
44.6 mm
Standard Deviation 29.99
44.1 mm
Standard Deviation 33.91
40.1 mm
Standard Deviation 32.15
Change From Baseline in Visual Analog Scale (Burning)
Day 1 (Change from Pre-CAE to Post-CAE)
14.2 mm
Standard Deviation 23.57
14.5 mm
Standard Deviation 22.27
17.7 mm
Standard Deviation 22.75
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 8
-1.9 mm
Standard Deviation 19.34
-4.5 mm
Standard Deviation 25.73
0.5 mm
Standard Deviation 16.66
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 15 (Pre-CAE)
-3.0 mm
Standard Deviation 19.75
-6.7 mm
Standard Deviation 24.08
0.3 mm
Standard Deviation 11.84
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 15 (Post-CAE)
-1.6 mm
Standard Deviation 23.56
-10.8 mm
Standard Deviation 24.27
-2.2 mm
Standard Deviation 16.90
Change From Baseline in Visual Analog Scale (Burning)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
1.4 mm
Standard Deviation 26.91
-3.5 mm
Standard Deviation 21.46
-2.6 mm
Standard Deviation 17.42
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 29 (Pre-CAE)
-3.0 mm
Standard Deviation 26.13
-6.6 mm
Standard Deviation 26.82
-0.4 mm
Standard Deviation 15.67
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 29 (Post-CAE)
-7.3 mm
Standard Deviation 21.43
-8.8 mm
Standard Deviation 26.93
-3.2 mm
Standard Deviation 16.00
Change From Baseline in Visual Analog Scale (Burning)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-0.2 mm
Standard Deviation 23.76
2.4 mm
Standard Deviation 25.72
-4.0 mm
Standard Deviation 24.77
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 57 (Pre-CAE)
-3.5 mm
Standard Deviation 27.19
-10.0 mm
Standard Deviation 31.76
-1.5 mm
Standard Deviation 16.19
Change From Baseline in Visual Analog Scale (Burning)
Change from Baseline: Day 57 (Post-CAE)
-1.3 mm
Standard Deviation 20.26
-10.3 mm
Standard Deviation 26.98
-4.6 mm
Standard Deviation 21.47
Change From Baseline in Visual Analog Scale (Burning)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
2.2 mm
Standard Deviation 33.08
2.2 mm
Standard Deviation 30.19
-3.0 mm
Standard Deviation 23.35

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Itching)
Day 1 Pre-CAE
28.6 mm
Standard Deviation 27.09
26.2 mm
Standard Deviation 29.26
26.8 mm
Standard Deviation 23.70
Change From Baseline in Visual Analog Scale (Itching)
Day 1 Post-CAE
37.0 mm
Standard Deviation 30.45
31.9 mm
Standard Deviation 33.26
35.0 mm
Standard Deviation 28.92
Change From Baseline in Visual Analog Scale (Itching)
Day 1 (Change from Pre-CAE to Post-CAE)
8.4 mm
Standard Deviation 21.67
5.2 mm
Standard Deviation 18.00
8.2 mm
Standard Deviation 22.76
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 8
-6.0 mm
Standard Deviation 19.05
-2.8 mm
Standard Deviation 22.23
0.5 mm
Standard Deviation 19.54
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 15 (Pre-CAE)
-3.1 mm
Standard Deviation 19.18
-4.5 mm
Standard Deviation 18.28
1.6 mm
Standard Deviation 20.27
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 15 (Post-CAE)
-8.0 mm
Standard Deviation 22.37
-2.4 mm
Standard Deviation 19.21
1.9 mm
Standard Deviation 16.56
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-4.9 mm
Standard Deviation 27.23
2.2 mm
Standard Deviation 21.18
0.3 mm
Standard Deviation 19.52
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 29 (Pre-CAE)
-2.7 mm
Standard Deviation 24.78
-9.5 mm
Standard Deviation 20.74
-1.7 mm
Standard Deviation 20.97
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 29 (Post-CAE)
-9.3 mm
Standard Deviation 19.47
-6.2 mm
Standard Deviation 23.64
2.2 mm
Standard Deviation 23.30
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-3.6 mm
Standard Deviation 15.78
5.2 mm
Standard Deviation 26.67
3.6 mm
Standard Deviation 25.99
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 57 (Pre-CAE)
-6.8 mm
Standard Deviation 22.73
-8.1 mm
Standard Deviation 27.02
-1.2 mm
Standard Deviation 23.65
Change From Baseline in Visual Analog Scale (Itching)
Change from Baseline: Day 57 (Post-CAE)
-7.0 mm
Standard Deviation 27.35
-5.7 mm
Standard Deviation 23.95
-2.1 mm
Standard Deviation 19.13
Change From Baseline in Visual Analog Scale (Itching)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-0.2 mm
Standard Deviation 25.65
4.7 mm
Standard Deviation 22.75
0.2 mm
Standard Deviation 26.94

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of foreign body by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Foreign Body)
Day 1 Pre-CAE
35.3 mm
Standard Deviation 25.95
35.1 mm
Standard Deviation 29.19
34.1 mm
Standard Deviation 25.87
Change From Baseline in Visual Analog Scale (Foreign Body)
Day 1 Post-CAE
45.1 mm
Standard Deviation 29.54
43.1 mm
Standard Deviation 31.03
49.9 mm
Standard Deviation 27.82
Change From Baseline in Visual Analog Scale (Foreign Body)
Day 1 (Change from Pre-CAE to Post-CAE)
9.8 mm
Standard Deviation 24.25
8.1 mm
Standard Deviation 22.30
15.8 mm
Standard Deviation 21.57
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 8
-6.2 mm
Standard Deviation 23.33
-3.4 mm
Standard Deviation 16.32
-0.4 mm
Standard Deviation 19.69
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 15 (Pre-CAE)
-7.8 mm
Standard Deviation 23.00
-1.3 mm
Standard Deviation 18.83
-5.0 mm
Standard Deviation 17.15
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 15 (Post-CAE)
-8.5 mm
Standard Deviation 20.45
-0.7 mm
Standard Deviation 21.90
-7.9 mm
Standard Deviation 18.96
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-0.6 mm
Standard Deviation 28.16
0.8 mm
Standard Deviation 27.76
-2.8 mm
Standard Deviation 20.72
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 29 (Pre-CAE)
-6.2 mm
Standard Deviation 28.69
-5.0 mm
Standard Deviation 16.97
-5.9 mm
Standard Deviation 26.37
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 29 (Post-CAE)
-8.6 mm
Standard Deviation 16.41
-4.7 mm
Standard Deviation 19.58
-1.1 mm
Standard Deviation 20.54
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
1.4 mm
Standard Deviation 19.18
2.6 mm
Standard Deviation 19.77
-0.6 mm
Standard Deviation 22.53
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 57 (Pre-CAE)
-9.3 mm
Standard Deviation 21.64
-7.3 mm
Standard Deviation 28.49
-5.2 mm
Standard Deviation 18.58
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from Baseline: Day 57 (Post-CAE)
-10.3 mm
Standard Deviation 23.81
-1.5 mm
Standard Deviation 27.06
-8.5 mm
Standard Deviation 19.20
Change From Baseline in Visual Analog Scale (Foreign Body)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-1.0 mm
Standard Deviation 27.77
6.9 mm
Standard Deviation 30.44
-3.7 mm
Standard Deviation 25.32

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of blurred vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Blurred Vision)
Day 1 Pre-CAE
18.5 mm
Standard Deviation 22.85
24.0 mm
Standard Deviation 27.00
26.9 mm
Standard Deviation 20.32
Change From Baseline in Visual Analog Scale (Blurred Vision)
Day 1 Post-CAE
26.4 mm
Standard Deviation 28.30
32.2 mm
Standard Deviation 30.82
41.1 mm
Standard Deviation 28.62
Change From Baseline in Visual Analog Scale (Blurred Vision)
Day 1 (Change from Pre-CAE to Post-CAE)
7.9 mm
Standard Deviation 18.33
8.2 mm
Standard Deviation 25.15
14.2 mm
Standard Deviation 20.98
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 8
2.5 mm
Standard Deviation 12.34
-4.5 mm
Standard Deviation 23.77
-4.2 mm
Standard Deviation 15.37
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 15 (Pre-CAE)
3.7 mm
Standard Deviation 11.94
-2.9 mm
Standard Deviation 19.40
-2.1 mm
Standard Deviation 15.80
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 15 (Post-CAE)
-1.1 mm
Standard Deviation 14.37
-7.3 mm
Standard Deviation 24.44
-8.7 mm
Standard Deviation 21.87
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-4.7 mm
Standard Deviation 16.88
-4.4 mm
Standard Deviation 23.96
-6.6 mm
Standard Deviation 27.55
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 29 (Pre-CAE)
-2.0 mm
Standard Deviation 14.81
-4.0 mm
Standard Deviation 18.45
-3.2 mm
Standard Deviation 16.29
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 29 (Post-CAE)
-5.9 mm
Standard Deviation 16.34
-7.9 mm
Standard Deviation 23.39
-6.1 mm
Standard Deviation 17.73
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-2.5 mm
Standard Deviation 19.24
-5.4 mm
Standard Deviation 21.62
-7.7 mm
Standard Deviation 21.60
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 57 (Pre-CAE)
0.5 mm
Standard Deviation 14.90
-3.0 mm
Standard Deviation 21.79
-1.2 mm
Standard Deviation 19.67
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from Baseline: Day 57 (Post-CAE)
-4.0 mm
Standard Deviation 19.15
-6.9 mm
Standard Deviation 24.83
-7.8 mm
Standard Deviation 21.29
Change From Baseline in Visual Analog Scale (Blurred Vision)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-4.5 mm
Standard Deviation 17.82
-3.3 mm
Standard Deviation 27.89
-6.5 mm
Standard Deviation 27.14

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Dryness)
Day 1 Pre-CAE
57.7 mm
Standard Deviation 20.98
58.6 mm
Standard Deviation 24.58
58.0 mm
Standard Deviation 22.90
Change From Baseline in Visual Analog Scale (Dryness)
Day 1 Post-CAE
74.2 mm
Standard Deviation 18.66
71.8 mm
Standard Deviation 21.47
75.0 mm
Standard Deviation 18.09
Change From Baseline in Visual Analog Scale (Dryness)
Day 1 (Change from Pre-CAE to Post-CAE)
16.5 mm
Standard Deviation 16.76
13.3 mm
Standard Deviation 17.80
17.0 mm
Standard Deviation 18.30
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 8
-4.7 mm
Standard Deviation 16.31
-2.1 mm
Standard Deviation 14.26
-1.6 mm
Standard Deviation 19.15
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 15 (Pre-CAE)
-6.7 mm
Standard Deviation 19.32
-7.4 mm
Standard Deviation 17.94
-4.2 mm
Standard Deviation 20.52
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 15 (Post-CAE)
-1.7 mm
Standard Deviation 12.82
-4.5 mm
Standard Deviation 16.69
-1.7 mm
Standard Deviation 17.81
Change From Baseline in Visual Analog Scale (Dryness)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
5.0 mm
Standard Deviation 21.30
3.0 mm
Standard Deviation 21.22
2.5 mm
Standard Deviation 22.67
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 29 (Pre-CAE)
-6.4 mm
Standard Deviation 23.40
-10.3 mm
Standard Deviation 19.89
-7.1 mm
Standard Deviation 25.61
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 29 (Post-CAE)
-5.8 mm
Standard Deviation 14.15
-7.1 mm
Standard Deviation 13.36
-5.1 mm
Standard Deviation 12.50
Change From Baseline in Visual Analog Scale (Dryness)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
2.3 mm
Standard Deviation 21.34
3.5 mm
Standard Deviation 20.86
0.6 mm
Standard Deviation 23.70
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 57 (Pre-CAE)
-11.7 mm
Standard Deviation 24.14
-11.3 mm
Standard Deviation 26.02
-8.4 mm
Standard Deviation 26.81
Change From Baseline in Visual Analog Scale (Dryness)
Change from Baseline: Day 57 (Post-CAE)
-8.3 mm
Standard Deviation 15.28
-3.8 mm
Standard Deviation 14.57
-7.7 mm
Standard Deviation 22.21
Change From Baseline in Visual Analog Scale (Dryness)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
3.3 mm
Standard Deviation 25.71
9.0 mm
Standard Deviation 24.83
1.7 mm
Standard Deviation 25.52

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 Pre-CAE
32.8 mm
Standard Deviation 28.41
37.4 mm
Standard Deviation 33.86
36.7 mm
Standard Deviation 29.19
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 Post-CAE
38.1 mm
Standard Deviation 29.80
39.8 mm
Standard Deviation 34.50
49.7 mm
Standard Deviation 32.33
Change From Baseline in Visual Analog Scale (Photophobia)
Day 1 (Change from Pre-CAE to Post-CAE)
5.3 mm
Standard Deviation 16.70
2.2 mm
Standard Deviation 21.20
13.0 mm
Standard Deviation 22.01
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 8
1.4 mm
Standard Deviation 16.17
-5.0 mm
Standard Deviation 21.40
-2.7 mm
Standard Deviation 18.46
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 15 (Pre-CAE)
-1.4 mm
Standard Deviation 16.19
-11.0 mm
Standard Deviation 22.36
-2.1 mm
Standard Deviation 18.17
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 15 (Post-CAE)
-2.4 mm
Standard Deviation 14.21
-5.7 mm
Standard Deviation 19.94
-8.8 mm
Standard Deviation 18.47
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-1.0 mm
Standard Deviation 19.59
5.8 mm
Standard Deviation 23.32
-6.7 mm
Standard Deviation 22.12
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 29 (Pre-CAE)
-3.1 mm
Standard Deviation 19.61
-7.3 mm
Standard Deviation 28.18
-3.1 mm
Standard Deviation 26.01
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 29 (Post-CAE)
-4.0 mm
Standard Deviation 13.84
-4.9 mm
Standard Deviation 18.11
-0.9 mm
Standard Deviation 18.18
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
3.0 mm
Standard Deviation 17.38
2.1 mm
Standard Deviation 13.89
-2.7 mm
Standard Deviation 27.46
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 57 (Pre-CAE)
-4.1 mm
Standard Deviation 20.87
-3.6 mm
Standard Deviation 26.95
-3.6 mm
Standard Deviation 22.33
Change From Baseline in Visual Analog Scale (Photophobia)
Change from Baseline: Day 57 (Post-CAE)
-4.0 mm
Standard Deviation 21.66
-2.3 mm
Standard Deviation 20.85
-10.4 mm
Standard Deviation 23.91
Change From Baseline in Visual Analog Scale (Photophobia)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
0.2 mm
Standard Deviation 28.34
1.5 mm
Standard Deviation 21.40
-6.5 mm
Standard Deviation 24.53

SECONDARY outcome

Timeframe: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 8
-2.2 mm
Standard Deviation 11.94
-1.8 mm
Standard Deviation 22.41
-2.6 mm
Standard Deviation 13.91
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 15 (Pre-CAE)
1.8 mm
Standard Deviation 20.34
-3.1 mm
Standard Deviation 22.90
-2.1 mm
Standard Deviation 14.54
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 15 (Post-CAE)
-3.9 mm
Standard Deviation 17.59
-2.0 mm
Standard Deviation 16.84
-2.8 mm
Standard Deviation 18.66
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)
-5.7 mm
Standard Deviation 19.81
1.5 mm
Standard Deviation 22.96
-0.8 mm
Standard Deviation 23.07
Change From Baseline in Visual Analog Scale (Pain)
Day 1 Pre-CAE
17.0 mm
Standard Deviation 22.31
17.8 mm
Standard Deviation 23.62
17.4 mm
Standard Deviation 21.01
Change From Baseline in Visual Analog Scale (Pain)
Day 1 Post-CAE
29.1 mm
Standard Deviation 30.50
26.3 mm
Standard Deviation 29.53
27.1 mm
Standard Deviation 29.83
Change From Baseline in Visual Analog Scale (Pain)
Day 1 (Change from Pre-CAE to Post-CAE)
12.1 mm
Standard Deviation 19.65
8.3 mm
Standard Deviation 15.81
9.7 mm
Standard Deviation 20.73
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 29 (Pre-CAE)
-3.8 mm
Standard Deviation 17.30
-3.3 mm
Standard Deviation 20.23
-3.4 mm
Standard Deviation 15.35
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 29 (Post-CAE)
-8.0 mm
Standard Deviation 16.05
-1.8 mm
Standard Deviation 18.57
-9.9 mm
Standard Deviation 18.61
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)
-3.3 mm
Standard Deviation 15.38
7.7 mm
Standard Deviation 16.05
-8.1 mm
Standard Deviation 20.05
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 57 (Pre-CAE)
-0.2 mm
Standard Deviation 22.85
-6.6 mm
Standard Deviation 24.80
-2.8 mm
Standard Deviation 14.32
Change From Baseline in Visual Analog Scale (Pain)
Change from Baseline: Day 57 (Post-CAE)
-10.9 mm
Standard Deviation 16.16
-4.1 mm
Standard Deviation 20.22
-2.1 mm
Standard Deviation 12.68
Change From Baseline in Visual Analog Scale (Pain)
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)
-10.7 mm
Standard Deviation 28.15
3.9 mm
Standard Deviation 21.67
0.7 mm
Standard Deviation 16.52

SECONDARY outcome

Timeframe: Baseline (Day 1); Days 8, 15, 29, and 57

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
Day 1
32.45 score on a scale
Standard Deviation 14.379
36.78 score on a scale
Standard Deviation 18.209
38.08 score on a scale
Standard Deviation 16.602
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
Change From Baseline: Day 8
-1.57 score on a scale
Standard Deviation 7.885
-0.87 score on a scale
Standard Deviation 7.889
-3.79 score on a scale
Standard Deviation 8.161
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
Change From Baseline: Day 15
-0.49 score on a scale
Standard Deviation 9.048
-2.98 score on a scale
Standard Deviation 10.361
-3.65 score on a scale
Standard Deviation 10.727
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
Change From Baseline: Day 29
-0.92 score on a scale
Standard Deviation 10.324
-4.42 score on a scale
Standard Deviation 12.540
-5.48 score on a scale
Standard Deviation 12.471
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
Change From Baseline: Day 57
-1.45 score on a scale
Standard Deviation 11.598
-3.33 score on a scale
Standard Deviation 11.978
-5.05 score on a scale
Standard Deviation 10.817

SECONDARY outcome

Timeframe: Upon instillation and 1 and 2 minutes post-instillation on Day 1

Population: The ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Ora Calibra® Drop Comfort Scale
Upon instillation on Day 1
2.8 score on a scale
Standard Deviation 2.25
3.6 score on a scale
Standard Deviation 2.40
3.3 score on a scale
Standard Deviation 2.69
Ora Calibra® Drop Comfort Scale
1 minute post-instillation on Day 1
2.0 score on a scale
Standard Deviation 1.86
2.6 score on a scale
Standard Deviation 1.93
2.3 score on a scale
Standard Deviation 1.84
Ora Calibra® Drop Comfort Scale
2 minutes post-instillation on Day 1
1.6 score on a scale
Standard Deviation 1.75
2.3 score on a scale
Standard Deviation 1.91
2.0 score on a scale
Standard Deviation 1.89

SECONDARY outcome

Timeframe: From Baseline (Day 1) to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=47 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=49 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Baseline: Daily average
2.74 score on a scale
Standard Deviation 0.884
2.82 score on a scale
Standard Deviation 0.934
2.66 score on a scale
Standard Deviation 0.789
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 1 to Day 7: Change from Baseline Daily Average
-0.13 score on a scale
Standard Deviation 0.326
-0.09 score on a scale
Standard Deviation 0.337
-0.07 score on a scale
Standard Deviation 0.376
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 8 to Day 14: Change from Baseline Daily Average
-0.24 score on a scale
Standard Deviation 0.430
-0.10 score on a scale
Standard Deviation 0.442
-0.09 score on a scale
Standard Deviation 0.510
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 15 to Day 21: Change from Baseline Daily Average
-0.21 score on a scale
Standard Deviation 0.534
-0.19 score on a scale
Standard Deviation 0.465
-0.13 score on a scale
Standard Deviation 0.628
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 22 to Day 28: Change from Baseline Daily Average
-0.23 score on a scale
Standard Deviation 0.558
-0.29 score on a scale
Standard Deviation 0.464
-0.24 score on a scale
Standard Deviation 0.650
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 29 to Day 35: Change from Baseline Daily Average
-0.18 score on a scale
Standard Deviation 0.600
-0.25 score on a scale
Standard Deviation 0.548
-0.15 score on a scale
Standard Deviation 0.623
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 36 to Day 42: Change from Baseline Daily Average
-0.28 score on a scale
Standard Deviation 0.597
-0.28 score on a scale
Standard Deviation 0.638
-0.18 score on a scale
Standard Deviation 0.638
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 43 to Day 49: Change from Baseline Daily Average
-0.34 score on a scale
Standard Deviation 0.636
-0.31 score on a scale
Standard Deviation 0.666
-0.16 score on a scale
Standard Deviation 0.662
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Average Day 50 to Day 56: Change from Baseline Daily Average
-0.38 score on a scale
Standard Deviation 0.713
-0.29 score on a scale
Standard Deviation 0.658
-0.16 score on a scale
Standard Deviation 0.674

SECONDARY outcome

Timeframe: From Baseline (Day 1) to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=49 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 50 to Day 56: Change from Baseline Daily Average
-0.27 score on a scale
Standard Deviation 0.571
-0.33 score on a scale
Standard Deviation 0.739
-0.11 score on a scale
Standard Deviation 0.527
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Baseline: Daily average
1.72 score on a scale
Standard Deviation 1.126
1.49 score on a scale
Standard Deviation 1.134
1.50 score on a scale
Standard Deviation 1.135
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 1 to Day 7: Change from Baseline Daily Average
-0.13 score on a scale
Standard Deviation 0.309
-0.08 score on a scale
Standard Deviation 0.398
-0.07 score on a scale
Standard Deviation 0.328
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 8 to Day 14: Change from Baseline Daily Average
-0.26 score on a scale
Standard Deviation 0.369
-0.17 score on a scale
Standard Deviation 0.438
-0.11 score on a scale
Standard Deviation 0.420
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 15 to Day 21: Change from Baseline Daily Average
-0.22 score on a scale
Standard Deviation 0.430
-0.21 score on a scale
Standard Deviation 0.498
-0.12 score on a scale
Standard Deviation 0.464
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 22 to Day 28: Change from Baseline Daily Average
-0.26 score on a scale
Standard Deviation 0.449
-0.29 score on a scale
Standard Deviation 0.511
-0.18 score on a scale
Standard Deviation 0.546
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 29 to Day 35: Change from Baseline Daily Average
-0.18 score on a scale
Standard Deviation 0.506
-0.28 score on a scale
Standard Deviation 0.523
-0.11 score on a scale
Standard Deviation 0.511
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 36 to Day 42: Change from Baseline Daily Average
-0.25 score on a scale
Standard Deviation 0.440
-0.35 score on a scale
Standard Deviation 0.701
-0.17 score on a scale
Standard Deviation 0.500
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Average Day 43 to Day 49: Change from Baseline Daily Average
-0.25 score on a scale
Standard Deviation 0.565
-0.33 score on a scale
Standard Deviation 0.647
-0.13 score on a scale
Standard Deviation 0.564

SECONDARY outcome

Timeframe: From Baseline (Day 1) to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=49 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Baseline: Daily average
2.88 score on a scale
Standard Deviation 0.793
2.96 score on a scale
Standard Deviation 0.968
2.99 score on a scale
Standard Deviation 0.669
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 1 to Day 7: Change from Baseline Daily Average
-0.13 score on a scale
Standard Deviation 0.391
-0.11 score on a scale
Standard Deviation 0.275
-0.10 score on a scale
Standard Deviation 0.383
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 8 to Day 14: Change from Baseline Daily Average
-0.20 score on a scale
Standard Deviation 0.505
-0.14 score on a scale
Standard Deviation 0.388
-0.13 score on a scale
Standard Deviation 0.504
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 15 to Day 21: Change from Baseline Daily Average
-0.20 score on a scale
Standard Deviation 0.615
-0.25 score on a scale
Standard Deviation 0.479
-0.13 score on a scale
Standard Deviation 0.621
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 22 to Day 28: Change from Baseline Daily Average
-0.23 score on a scale
Standard Deviation 0.620
-0.30 score on a scale
Standard Deviation 0.519
-0.29 score on a scale
Standard Deviation 0.659
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 29 to Day 35: Change from Baseline Daily Average
-0.17 score on a scale
Standard Deviation 0.691
-0.29 score on a scale
Standard Deviation 0.485
-0.21 score on a scale
Standard Deviation 0.690
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 36 to Day 42: Change from Baseline Daily Average
-0.30 score on a scale
Standard Deviation 0.680
-0.32 score on a scale
Standard Deviation 0.628
-0.23 score on a scale
Standard Deviation 0.677
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 43 to Day 49: Change from Baseline Daily Average
-0.35 score on a scale
Standard Deviation 0.728
-0.31 score on a scale
Standard Deviation 0.704
-0.25 score on a scale
Standard Deviation 0.768
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Average Day 50 to Day 56: Change from Baseline Daily Average
-0.40 score on a scale
Standard Deviation 0.793
-0.29 score on a scale
Standard Deviation 0.703
-0.27 score on a scale
Standard Deviation 0.812

SECONDARY outcome

Timeframe: From Baseline (Day 1) to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=49 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 29 to Day 35: Change from Baseline Daily Average
-0.21 score on a scale
Standard Deviation 0.724
-0.22 score on a scale
Standard Deviation 0.554
-0.18 score on a scale
Standard Deviation 0.627
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Baseline: Daily average
2.14 score on a scale
Standard Deviation 0.988
1.84 score on a scale
Standard Deviation 1.248
2.07 score on a scale
Standard Deviation 1.177
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 1 to Day 7: Change from Baseline Daily Average
-0.19 score on a scale
Standard Deviation 0.450
-0.07 score on a scale
Standard Deviation 0.331
-0.03 score on a scale
Standard Deviation 0.407
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 8 to Day 14: Change from Baseline Daily Average
-0.27 score on a scale
Standard Deviation 0.555
-0.07 score on a scale
Standard Deviation 0.500
-0.08 score on a scale
Standard Deviation 0.555
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 15 to Day 21: Change from Baseline Daily Average
-0.22 score on a scale
Standard Deviation 0.594
-0.16 score on a scale
Standard Deviation 0.540
-0.14 score on a scale
Standard Deviation 0.554
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 22 to Day 28: Change from Baseline Daily Average
-0.26 score on a scale
Standard Deviation 0.628
-0.21 score on a scale
Standard Deviation 0.615
-0.23 score on a scale
Standard Deviation 0.655
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 36 to Day 42: Change from Baseline Daily Average
-0.35 score on a scale
Standard Deviation 0.682
-0.18 score on a scale
Standard Deviation 0.642
-0.18 score on a scale
Standard Deviation 0.561
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 43 to Day 49: Change from Baseline Daily Average
-0.38 score on a scale
Standard Deviation 0.682
-0.16 score on a scale
Standard Deviation 0.833
-0.16 score on a scale
Standard Deviation 0.666
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Average Day 50 to Day 56: Change from Baseline Daily Average
-0.36 score on a scale
Standard Deviation 0.764
-0.11 score on a scale
Standard Deviation 0.959
-0.18 score on a scale
Standard Deviation 0.708

SECONDARY outcome

Timeframe: From Baseline (Day 1) to Day 56

Population: Number of participants analyzed included participants in ITT Population with available data. The analysis was carried out with observed data only.

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Outcome measures

Outcome measures
Measure
0.10% HL036 Ophthalmic Solution
n=49 Participants
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 Participants
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 Participants
Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 1 to Day 7: Change from Baseline Daily Average
-0.14 score on a scale
Standard Deviation 0.349
-0.13 score on a scale
Standard Deviation 0.327
-0.11 score on a scale
Standard Deviation 0.342
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 8 to Day 14: Change from Baseline Daily Average
-0.24 score on a scale
Standard Deviation 0.409
-0.12 score on a scale
Standard Deviation 0.438
-0.14 score on a scale
Standard Deviation 0.469
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 22 to Day 28: Change from Baseline Daily Average
-0.12 score on a scale
Standard Deviation 0.517
-0.28 score on a scale
Standard Deviation 0.533
-0.24 score on a scale
Standard Deviation 0.546
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 43 to Day 49: Change from Baseline Daily Average
-0.24 score on a scale
Standard Deviation 0.553
-0.27 score on a scale
Standard Deviation 0.647
-0.16 score on a scale
Standard Deviation 0.612
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Baseline: Daily average
1.53 score on a scale
Standard Deviation 1.113
1.20 score on a scale
Standard Deviation 1.127
1.26 score on a scale
Standard Deviation 1.075
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 15 to Day 21: Change from Baseline Daily Average
-0.16 score on a scale
Standard Deviation 0.428
-0.22 score on a scale
Standard Deviation 0.515
-0.20 score on a scale
Standard Deviation 0.455
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 29 to Day 35: Change from Baseline Daily Average
-0.11 score on a scale
Standard Deviation 0.572
-0.28 score on a scale
Standard Deviation 0.538
-0.21 score on a scale
Standard Deviation 0.517
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 36 to Day 42: Change from Baseline Daily Average
-0.22 score on a scale
Standard Deviation 0.564
-0.32 score on a scale
Standard Deviation 0.631
-0.20 score on a scale
Standard Deviation 0.514
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Average Day 50 to Day 56: Change from Baseline Daily Average
-0.22 score on a scale
Standard Deviation 0.575
-0.28 score on a scale
Standard Deviation 0.744
-0.15 score on a scale
Standard Deviation 0.577

Adverse Events

0.10% HL036 Ophthalmic Solution

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

0.25% HL036 Ophthalmic Solution

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
0.10% HL036 Ophthalmic Solution
n=50 participants at risk
Participants self-administered HL036 0.10 % ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
0.25% HL036 Ophthalmic Solution
n=50 participants at risk
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Placebo
n=50 participants at risk
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Eye disorders
Conjunctivitis allergic
6.0%
3/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
8.0%
4/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
0.00%
0/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
Eye disorders
Visual acuity reduced
6.0%
3/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
0.00%
0/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
0.00%
0/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
General disorders
Instillation site pain
4.0%
2/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
12.0%
6/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
2.0%
1/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
Infections and infestations
Nasopharyngitis
10.0%
5/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
6.0%
3/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.
16.0%
8/50 • Baseline up to 8 weeks
Safety population included all randomized subjects who have received at least one dose of the investigational product.

Additional Information

Project Manager

Hanall Biopharma

Phone: 82-222041763

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place